Recently we have shown that docosahexaenoic acid complexed to albumin (DHA-Alb) is neuroprotective after experimental stroke in young rats. The purpose of this study was to determine whether treatment with DHAAlb would be protective in aged rats after focal cerebral ischemia. Isoflurane/nitrous oxide-anesthetized normothermic (brain temperature 36-36.5°C) Sprague-Dawley aged rats (18-months old) received 2 h middle cerebral artery occlusion (MCAo) by poly-L-lysine-coated intraluminal suture. The neurological status was evaluated during occlusion (60 min) and on days 1, 2, 3 and 7 after MCAo; a grading scale of 0-12 was employed. DHA (5 mg/kg), Alb (0.63 g/kg), DHA-Alb (5 mg/kg + 0.63 g/kg) or saline was administered i.v. 3 h after onset of stroke (n = 8-10 per group). Ex vivo T2-weighted imaging (T2WI) of the brains was conducted on an 11.7T MRI on day 7 and 3D reconstructions were generated. Infarct volumes and number of GFAP (reactive astrocytes), ED-1 (activated microglia/microphages), NeuN (neurons)-positive cells and SMI-71 (positive vessels) were counted in the cortex and striatum at the level of the central lesion. Physiological variables were entirely comparable between groups. Animals treated with DHA-Alb showed significantly improved neurological scores compared to vehicle rats; 33% improvement on day 1; 39% on day 2; 41% on day 3; and 45% on day 7. Total and cortical lesion volumes computed from T2WI were significantly reduced by DHA-Alb treatment (62 and 69%, respectively). In addition, treatment with DHA-Alb reduced cortical and total brain infarction while promoting cell survival. We conclude that DHA-Alb therapy is highly neuroprotective in aged rats following focal cerebral ischemia and has potential for the effective treatment of ischemic stroke in aged individuals.
Introduction
Stroke is a major cause of death and disability in the elderly. However, experimental stroke research, including the evaluation of neuroprotective drugs, has almost universally relied on use of young animals despite the importance of aging on cerebrovascular disease in humans. This might reflect in part the considerable difficulties to establish a reproducible stroke model in aged animals. In addition, aging has been associated with a significant increase in cerebral infarct size and high mortality (Davis et al., 1995) . The need to evaluate and develop an effective treatment for elderly stroke patients remains paramount. Thus animal studies which investigate the mechanisms and efficacy of novel treatments specifically in aged animal remain ideal.
High-dose human albumin (Alb) therapy is strongly neuroprotective in animal models of focal cerebral ischemia (Belayev et al., 2001) , as well as in global cerebral ischemia (Belayev et al., 1999b) and traumatic brain injury (Belayev et al., 1999a) . The neuroprotective efficacy of albumin is attributed to its multifunctional properties, which include antioxidant action, hemodilution and oncotic effects, binding of copper ions, fatty-acid transport, preservation of endothelial integrity, platelet antiaggregatory effects and decreased red blood cell sedimentation under low-flow conditions (Belayev et al., 1997 (Belayev et al., , 1998 (Belayev et al., , 2002 . Recently, Alb was studied in a phase III clinical trial for acute ischemic stroke (Ginsberg et al., 2011) , but the trial was stopped, because it was associated with more adverse effects than saline control (administration of high-dose albumin in dose of 2 g/kg expanded intravascular volume, which leads to pulmonary edema in 13% of patients).
Recent studies have established that omega-3 fatty acids reduce inflammation and may help lower risk of chronic diseases such as heart disease, cancer, and arthritis. Docosahexaenoic acid (DHA; 22:6, n−3), Neurobiology of Disease 62 (2014) 1-7
